# Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

> **NCT04781998** · PHASE4 · COMPLETED · sponsor: **Anders Fink-Jensen, MD, DMSci** · enrollment: 24 (actual)

## Conditions studied

- Mental Disorder
- Metabolic Disturbance
- Feasibility
- Overweight and Obesity
- Liraglutide

## Interventions

- **DRUG:** liraglutide 3 mg (Saxenda®) once-daily

## Key facts

- **NCT ID:** NCT04781998
- **Lead sponsor:** Anders Fink-Jensen, MD, DMSci
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-09-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781998, "Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04781998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*